Probucol and atorvastatin decrease urinary 8-hydroxy-2′-deoxyguanosine in patients with diabetes and hypercholesterolemia

DOI Web Site PubMed 被引用文献5件 参考文献67件 オープンアクセス
  • Koide Nobukiyo
    Center of Diabetes, Endocrinology and Metabolism, Sakura Hospital, Toho University, Chiba, Japan.
  • Ohira Masahiro
    Center of Diabetes, Endocrinology and Metabolism, Sakura Hospital, Toho University, Chiba, Japan.
  • Ebisuno Mariko
    Center of Diabetes, Endocrinology and Metabolism, Sakura Hospital, Toho University, Chiba, Japan.
  • Saiki Atsuhito
    Center of Diabetes, Endocrinology and Metabolism, Sakura Hospital, Toho University, Chiba, Japan.
  • Takeyoshi Murano
    Department of Clinical Laboratory Medicine, Sakura Hospital, Toho University, Chiba, Japan.
  • Oyama Tomokazu
    Center of Diabetes, Endocrinology and Metabolism, Sakura Hospital, Toho University, Chiba, Japan.
  • Shirai Koji
    Department of Internal Medicine, Sakura Hospital, Toho University, Chiba, Japan.
  • Endo Kei
    Center of Diabetes, Endocrinology and Metabolism, Sakura Hospital, Toho University, Chiba, Japan.
  • Miyashita Yoh
    Center of Diabetes, Endocrinology and Metabolism, Sakura Hospital, Toho University, Chiba, Japan.
  • Sasaki Hidehisa
    Pharmaceutical Department, Sakura Hospital, Toho University, Chiba, Japan.

書誌事項

タイトル別名
  • Probucol and Atorvastatin Decrease Urinary 8-Hydroxy-2'-deoxyguanosine in Patients with Diabetes and Hypercholesterolemia
公開日
2006
DOI
  • 10.5551/jat.13.68
公開者
一般社団法人 日本動脈硬化学会

この論文をさがす

説明

To clarify whether probucol and statins suppress oxidative stress in diabetic patients, we studied the effects of probucol and the statin atorvastatin on urinary 8-hydroxy-2’deoxyguanosine (8-OHdG) levels in diabetics with hypercholesterolemia. A randomized, open study was performed on a total of 36 patients with type 2 diabetes and hypercholesterolemia. The patients were randomly assigned to a probucol group (500 mg/day, n = 18) or an atorvastatin group (10 mg/day, n = 18). During three months, total- and LDL-cholesterol decreased significantly in both groups. LDL-cholesterol was significantly lower in the atorvastatin group than probucol group. HDL-C decreased significantly in the probucol group and did not change in the atorvastatin group. 8-OHdG decreased significantly in both groups after 3 months; 12.4 ± 7.5 to 8.1 ± 4.2 ng/mg/Cr in the atorvastatin group (p < 0.05) and 12.3 ± 8.8 to 6.8 ± 2.6 ng/mg/Cr in the probucol group (p < 0.05), and these changes did not differ significantly between the two groups. But, in patients with high 8-OHdG levels (more than 10 ng/mg/Cr) before administration, urinary 8-OHdG decreased significantly from 19.5 ± 4.9 to 9.2 ± 3.4 ng/mg Cr (p < 0.01) in the atorvastatin group, and from 19.7 ± 8.2 to 6.67 ± 2.2 ng/mg Cr (p < 0.01) in the probucol group. Urinary 8-OHdG was significantly lower in the probucol group than in the atorvastatin group after the second and third months of administration (p < 0.05). These results suggest that while probucol and atorvastatin both reduce systemic oxidative stress, probucol might be the more useful in patients with strong oxidative stress.

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (67)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ